GLS and prostate cancer: Mukha et al. reported that GLS-driven Gln metabolism is a regulator of radiotherapy tolerance in prostate cancer (PCa) and that high expression of GLS 1 and c-MYC, key regulators of Gln, are significantly associated with reduced progression-free survival in prostate cancer patients treated with radiotherapy.